{"id":29194,"date":"2023-11-07T10:45:03","date_gmt":"2023-11-07T10:45:03","guid":{"rendered":"https:\/\/cannabishealthnews.co.uk\/?p=29194"},"modified":"2023-11-07T10:45:06","modified_gmt":"2023-11-07T10:45:06","slug":"france-takes-major-step-towards-medical-cannabis-generalisation","status":"publish","type":"post","link":"https:\/\/cannabishealthnews.co.uk\/2023\/11\/07\/france-takes-major-step-towards-medical-cannabis-generalisation\/","title":{"rendered":"France takes major step towards medical cannabis generalisation"},"content":{"rendered":"
Via Business of Cannabis <\/a><\/p>\n On Monday, October 23, the government tabled an amendment to the Social Security Financing Bill (PLFSS) concerning medical cannabis, bringing it into France\u2019s general medical framework for the first time.<\/p>\n Now, according to the new proposals, medical cannabis products will receive a \u2018temporary authorisation\u2019 for five years, with scope for these to be renewed by French authorities indefinitely.<\/p>\n Benjamin-Alexandre Jeanroy of Paris-based Augur Associates<\/a> told us that while this represents a step towards fully-fledged generalisation, it \u2018is a very important step because it brings medical cannabis into general law\u2019.<\/p>\n \u201cThat is a huge victory in itself\u2026While it\u2019s still hard for patients, who still have to try every other treatment before being prescribed, it\u2019s now part of the tool box for doctors to prescribe and patients to access.\u201d<\/p>\n He added that once both chambers pass the PLFSS, there will be the capacity to start building a medical cannabis industry in France as pre-redacted ministerial decrees are expected to be published in the in the aftermath.<\/p>\n France launched its medical cannabis experiment in 2021, offering around 3,000 patients free cannabis products with an initial intended run-time of two years.<\/p>\n The trial was intended \u2018to evaluate, in a real situation, the recommendations of the committee in terms of prescribing and dispensing conditions and the adherence of health professionals and patients to these conditions\u2019, providing safety and efficacy data as a \u2018secondary objective\u2019.<\/p>\n Patients and industry stakeholders alike had expected that the experiment would be a near certain precursor to full regulation, yet with the experiment due to come to an end in March 2024, any mention of this was excluded from France\u2019s PLFSS when it was published last month.<\/a><\/p>\n Following considerable pushback from the industry amid fears that not only would the thousands of patients lose access to their medicine, but also that the medical cannabis programme would be dead in the water, France\u2019s Minister of Health confirmed<\/a> in mid-October that the government would table an amendment to the bill which would address the issue.<\/p>\n This amendment was tabled last week, providing plans for a temporary status for medical cannabis products. Here are the key points:<\/p>\n While the move has been widely welcomed by the industry, which has rightly attributed the amendment to continued pressure from campaign groups, a number of key questions remain.<\/p>\n Primarily, campaigners have questioned why access remains so restrictive for patients, who need to have tried all other avenues of treatment before they can be considered for medical cannabis.<\/p>\n Furthermore, as no budget has yet been set for the generalisation, many have questioned whether reimbursement will continue as it has with the experiment.<\/p>\n French drug policy reform group L360 also raised concerns<\/a> regarding data protection, as the current text says that companies supplying medical cannabis to patients must collect data on patient consumption and their reaction to treatment.<\/p>\n This article was originally published by Business of Cannabis<\/a> and is reprinted here with permission. <\/em><\/p>\n\n\n\nFollowing months of uncertainty and doubt, thousands of medical cannabis patients in France can now breathe a sigh of relief after the government finally confirmed that access to their treatment will continue.<\/h3>\n
What Happened?<\/strong><\/h4>\n
The Amendment<\/strong><\/h4>\n
\n